ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3028% below fair value
$13.56−0.07 (-0.51%)
Close on Nov 18, 2026Market cap $3.04BP/E 19.4Yield –
ADMA Biologics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
ADMA Biologics's pe ratio was 18.8× on Nov 11, 2026, against 22.6× a year earlier. Over the last 2 years it ranged from 11.7× to 142.8×, with a median of 21.5×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 18.8× | −2.6 |
| 2025 | Dec 31, 2025 | 21.5× | −39.8 |
| 2024 | Dec 31, 2024 | 61.3× | – |
See a number that looks wrong?